Showing 5161-5170 of 5621 results for "".
- Alimera Announces Iluvien Regulatory Approval in Australia for the Treatment of DMEhttps://modernod.com/news/alimera-announces-iluvien-regulatory-approval-in-australia-for-the-treatment-of-dme/2479552/Alimera Sciences announced that the Australian Therapeutic Goods Administration (TGA), the division of the Australian Department of Health that oversees the availability of medical products, has approved Iluvien (190 micrograms intravitreal implant in applicator) for the treatment of diabetic mac
- Staar Surgical Announces Submission of Presbyopia Clinical Trial Datahttps://modernod.com/news/staar-surgical-announces-submission-of-presbyopia-clinical-trial-data/2479554/Staar Surgical announced the submission of its multisite European pivotal clinical trial data for the EVO+ Visian ICL with Aspheric (EDOF) Optic, a lens that is designed to provide correction or reduction of myopia or hyperopia and presbyopia. Results from the clinical trial were submitted to DEK
- Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edemahttps://modernod.com/news/perspective-protocol-v-sheds-light-on-managing-mild-diabetic-macular-edema/2479555/When it comes to the treatment of diabetic macular edema (DME), ophthalmologists have overwhelming evidence to guide their decision-making—but only up to a point. DME consists of three clinical subcategories: center-involved DME (CI-DME) with visual acuity (VA) impairment, CI-DME with good
- US Outlines Plans to Allow Importation of Certain Prescription Drugs From Canada, Other Countrieshttps://modernod.com/news/us-outlines-plans-to-allow-importation-of-certain-prescription-drugs-from-canada-other-countries/2479556/The US Department of Health and Human Services (HHS) on Wednesday outlined details of two potential pathways that will allow the importation of certain prescription medicines originally intended for foreign markets. The announcement comes the day after HHS Secretary Alex Azar confirmed that Presi
- CMS Issues Proposed 2020 ASC Payment Rulehttps://modernod.com/news/cms-issues-proposed-2020-asc-payment-rule/2479563/On July 29, the Centers for Medicare and Medicaid Services (CMS) issued its proposed CY 2020 payment rate regulation for hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs). The proposed regulation will soon be published in the Federal Register. The Outpatient Ophthalmic
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmologyhttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology/2476783/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education, and patient care, this year marks the 18th time that Bascom P
- Now Optics Launches New Advertising Campaign ‘The Perfect Fit’https://modernod.com/news/now-optics-launches-new-advertising-campaign-the-perfect-fit/2476780/Now Optics, which provides eyewear under the retail brands Stanton Optical and My Eyelab, has announced a new advertising campaign, ‘The Perfect Fit.’ Developed in conjunction with its agency, Barkley, ‘The Perfect Fit’ highlights walk-in eye exam appointments, eyeglasses and eyewear assor
- Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpointshttps://modernod.com/news/alkahest-phase-2a-study-akst4290-202-in-refractory-wet-amd-meets-primary-and-secondary-endpoints/2476778/Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 w
- European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10https://modernod.com/news/european-medicines-agency-grants-prime-access-to-proqrs-sepofarsen-for-lebers-congenital-amaurosis-10/2476779/ProQR Therapeutics announced that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the Priority Medicines (PRIME) program by the European Med
- Okayama University Research: Prosthetics for Retinal Stimulationhttps://modernod.com/news/okayama-university-research-prosthetics-for-retinal-stimulation/2476774/In a study recently published in Advanced Biomedical Engineering, researchers at Okayama University in Japan report a thin photoelectric film which can stimulate degenerated retinal tissues of the eye. Using electric signals to stimulate tissues is the basis of several medical devic